NVCR (NovoCure Limited) Net earnings per share (EPS TTM)

NovoCure Limited (NVCR) is developing innovative Tumor Treating Fields therapy to combat brain tumors. This annual net income per share figure on GURU.Markets reflects the business adaptation, where the value of -1.08 serves as the current metric. The company is mitigating risks by expanding the application of the method to lung cancer and is striving for international recognition of its systems for treating solid tumors.
Metric breakdowns and analytics for NovoCure Limited (NVCR)

High costs associated with the direct delivery of oncology equipment to patients directly impact the operating margin, which is reflected in the calculation of net earnings per share. By analyzing the current trailing 12-month EPS, an investor sees the final financial result adjusted for the volume of issuance, allowing for an objective assessment of the business model's sustainability and the justification of the market value of NovoCure Limited (NVCR).